eligibility_summary
Adults with confirmed r/r lymphoma: B‑NHL (DLBCL, FL incl. FL3b, MCL, HGBL‑NOS, MZL, transformed lymphomas incl. MCL) or T‑cell lymphoma, with consent waiver. Must have received or be receiving cellular immunotherapy (CIK, TIL, DC‑CIK, CAR‑T/CAR‑NK/CAR‑M, NK or macrophage therapy, TCR‑T, dendritic cell therapy). No exclusion criteria specified.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Observational registry of cellular immunotherapies for relapsed/refractory NHL. Recorded interventions include: CAR‑T (gene‑modified T cells), CAR‑NK (gene‑modified NK cells), CAR‑M (gene‑modified macrophages), TCR‑T (engineered TCR T cells), TIL (expanded tumor‑infiltrating lymphocytes), CIK and DC‑CIK (cytokine‑induced killer cells ± dendritic‑cell priming), NK‑cell therapy, and dendritic‑cell vaccines, trial arm highlights CAR‑T. Mechanisms: CAR constructs enable antigen‑specific, MHC‑independent tumor recognition and killing, TCR‑T mediates peptide–HLA–restricted cytotoxicity, TIL/CIK/NK kill via perforin/granzyme and activating‑receptor pathways, DC therapies boost antigen presentation and T‑cell priming, CAR‑M enhances CAR‑directed phagocytosis and TME remodeling. Targets: lymphoma cells (B‑ or T‑cell), engaging immune effector pathways. Type: cellular/gene‑modified immunotherapies.